890 related articles for article (PubMed ID: 25726502)
1. Alteplase versus tenecteplase for thrombolysis after ischaemic stroke (ATTEST): a phase 2, randomised, open-label, blinded endpoint study.
Huang X; Cheripelli BK; Lloyd SM; Kalladka D; Moreton FC; Siddiqui A; Ford I; Muir KW
Lancet Neurol; 2015 Apr; 14(4):368-76. PubMed ID: 25726502
[TBL] [Abstract][Full Text] [Related]
2. Tenecteplase versus alteplase for management of acute ischaemic stroke (NOR-TEST): a phase 3, randomised, open-label, blinded endpoint trial.
Logallo N; Novotny V; Assmus J; Kvistad CE; Alteheld L; Rønning OM; Thommessen B; Amthor KF; Ihle-Hansen H; Kurz M; Tobro H; Kaur K; Stankiewicz M; Carlsson M; Morsund Å; Idicula T; Aamodt AH; Lund C; Næss H; Waje-Andreassen U; Thomassen L
Lancet Neurol; 2017 Oct; 16(10):781-788. PubMed ID: 28780236
[TBL] [Abstract][Full Text] [Related]
3. Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway (NOR-TEST 2, part A): a phase 3, randomised, open-label, blinded endpoint, non-inferiority trial.
Kvistad CE; Næss H; Helleberg BH; Idicula T; Hagberg G; Nordby LM; Jenssen KN; Tobro H; Rörholt DM; Kaur K; Eltoft A; Evensen K; Haasz J; Singaravel G; Fromm A; Thomassen L
Lancet Neurol; 2022 Jun; 21(6):511-519. PubMed ID: 35525250
[TBL] [Abstract][Full Text] [Related]
4. Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial.
Menon BK; Buck BH; Singh N; Deschaintre Y; Almekhlafi MA; Coutts SB; Thirunavukkarasu S; Khosravani H; Appireddy R; Moreau F; Gubitz G; Tkach A; Catanese L; Dowlatshahi D; Medvedev G; Mandzia J; Pikula A; Shankar J; Williams H; Field TS; Manosalva A; Siddiqui M; Zafar A; Imoukhuede O; Hunter G; Demchuk AM; Mishra S; Gioia LC; Jalini S; Cayer C; Phillips S; Elamin E; Shoamanesh A; Subramaniam S; Kate M; Jacquin G; Camden MC; Benali F; Alhabli I; Bala F; Horn M; Stotts G; Hill MD; Gladstone DJ; Poppe A; Sehgal A; Zhang Q; Lethebe BC; Doram C; Ademola A; Shamy M; Kenney C; Sajobi TT; Swartz RH;
Lancet; 2022 Jul; 400(10347):161-169. PubMed ID: 35779553
[TBL] [Abstract][Full Text] [Related]
5. Tenecteplase versus alteplase in acute ischaemic cerebrovascular events (TRACE-2): a phase 3, multicentre, open-label, randomised controlled, non-inferiority trial.
Wang Y; Li S; Pan Y; Li H; Parsons MW; Campbell BCV; Schwamm LH; Fisher M; Che F; Dai H; Li D; Li R; Wang J; Wang Y; Zhao X; Li Z; Zheng H; Xiong Y; Meng X;
Lancet; 2023 Feb; 401(10377):645-654. PubMed ID: 36774935
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of tenecteplase in patients with wake-up stroke assessed by non-contrast CT (TWIST): a multicentre, open-label, randomised controlled trial.
Roaldsen MB; Eltoft A; Wilsgaard T; Christensen H; Engelter ST; Indredavik B; Jatužis D; Karelis G; Kõrv J; Lundström E; Petersson J; Putaala J; Søyland MH; Tveiten A; Bivard A; Johnsen SH; Mazya MV; Werring DJ; Wu TY; De Marchis GM; Robinson TG; Mathiesen EB;
Lancet Neurol; 2023 Feb; 22(2):117-126. PubMed ID: 36549308
[TBL] [Abstract][Full Text] [Related]
7. Comparison of tenecteplase with alteplase for the early treatment of ischaemic stroke in the Melbourne Mobile Stroke Unit (TASTE-A): a phase 2, randomised, open-label trial.
Bivard A; Zhao H; Churilov L; Campbell BCV; Coote S; Yassi N; Yan B; Valente M; Sharobeam A; Balabanski AH; Dos Santos A; Ng JL; Yogendrakumar V; Ng F; Langenberg F; Easton D; Warwick A; Mackey E; MacDonald A; Sharma G; Stephenson M; Smith K; Anderson D; Choi P; Thijs V; Ma H; Cloud GC; Wijeratne T; Olenko L; Italiano D; Davis SM; Donnan GA; Parsons MW;
Lancet Neurol; 2022 Jun; 21(6):520-527. PubMed ID: 35525251
[TBL] [Abstract][Full Text] [Related]
8. Extending thrombolysis to 4·5-9 h and wake-up stroke using perfusion imaging: a systematic review and meta-analysis of individual patient data.
Campbell BCV; Ma H; Ringleb PA; Parsons MW; Churilov L; Bendszus M; Levi CR; Hsu C; Kleinig TJ; Fatar M; Leys D; Molina C; Wijeratne T; Curtze S; Dewey HM; Barber PA; Butcher KS; De Silva DA; Bladin CF; Yassi N; Pfaff JAR; Sharma G; Bivard A; Desmond PM; Schwab S; Schellinger PD; Yan B; Mitchell PJ; Serena J; Toni D; Thijs V; Hacke W; Davis SM; Donnan GA;
Lancet; 2019 Jul; 394(10193):139-147. PubMed ID: 31128925
[TBL] [Abstract][Full Text] [Related]
9. The Norwegian tenecteplase stroke trial (NOR-TEST): randomised controlled trial of tenecteplase vs. alteplase in acute ischaemic stroke.
Logallo N; Kvistad CE; Nacu A; Naess H; Waje-Andreassen U; Asmuss J; Aamodt AH; Lund C; Kurz MW; Rønning OM; Salvesen R; Idicula TT; Thomassen L
BMC Neurol; 2014 May; 14():106. PubMed ID: 24886064
[TBL] [Abstract][Full Text] [Related]
10. A randomized trial of tenecteplase versus alteplase for acute ischemic stroke.
Parsons M; Spratt N; Bivard A; Campbell B; Chung K; Miteff F; O'Brien B; Bladin C; McElduff P; Allen C; Bateman G; Donnan G; Davis S; Levi C
N Engl J Med; 2012 Mar; 366(12):1099-107. PubMed ID: 22435369
[TBL] [Abstract][Full Text] [Related]
11. Intensive blood pressure reduction with intravenous thrombolysis therapy for acute ischaemic stroke (ENCHANTED): an international, randomised, open-label, blinded-endpoint, phase 3 trial.
Anderson CS; Huang Y; Lindley RI; Chen X; Arima H; Chen G; Li Q; Billot L; Delcourt C; Bath PM; Broderick JP; Demchuk AM; Donnan GA; Durham AC; Lavados PM; Lee TH; Levi C; Martins SO; Olavarria VV; Pandian JD; Parsons MW; Pontes-Neto OM; Ricci S; Sato S; Sharma VK; Silva F; Song L; Thang NH; Wardlaw JM; Wang JG; Wang X; Woodward M; Chalmers J; Robinson TG;
Lancet; 2019 Mar; 393(10174):877-888. PubMed ID: 30739745
[TBL] [Abstract][Full Text] [Related]
12. Tenecteplase versus alteplase for stroke thrombolysis evaluation (TASTE): A multicentre, prospective, randomized, open-label, blinded-endpoint, controlled phase III non-inferiority trial protocol.
Bivard A; Garcia-Esperon C; Churilov L; Spratt N; Russell M; Campbell BC; Choi P; Kleinig T; Ma H; Markus H; Molina C; Hsu C; Tsai CH; Meretoja A; Strbian D; Butcher K; Wu T; Davis S; Donnan G; Levi C; Parsons M
Int J Stroke; 2023 Jul; 18(6):751-756. PubMed ID: 36655938
[TBL] [Abstract][Full Text] [Related]
13. Tenecteplase versus Alteplase before Thrombectomy for Ischemic Stroke.
Campbell BCV; Mitchell PJ; Churilov L; Yassi N; Kleinig TJ; Dowling RJ; Yan B; Bush SJ; Dewey HM; Thijs V; Scroop R; Simpson M; Brooks M; Asadi H; Wu TY; Shah DG; Wijeratne T; Ang T; Miteff F; Levi CR; Rodrigues E; Zhao H; Salvaris P; Garcia-Esperon C; Bailey P; Rice H; de Villiers L; Brown H; Redmond K; Leggett D; Fink JN; Collecutt W; Wong AA; Muller C; Coulthard A; Mitchell K; Clouston J; Mahady K; Field D; Ma H; Phan TG; Chong W; Chandra RV; Slater LA; Krause M; Harrington TJ; Faulder KC; Steinfort BS; Bladin CF; Sharma G; Desmond PM; Parsons MW; Donnan GA; Davis SM;
N Engl J Med; 2018 Apr; 378(17):1573-1582. PubMed ID: 29694815
[TBL] [Abstract][Full Text] [Related]
14. Tenecteplase versus Alteplase for Stroke Thrombolysis Evaluation Trial in the Ambulance (Mobile Stroke Unit-TASTE-A): protocol for a prospective randomised, open-label, blinded endpoint, phase II superiority trial of tenecteplase versus alteplase for ischaemic stroke patients presenting within 4.5 hours of symptom onset to the mobile stroke unit.
Bivard A; Zhao H; Coote S; Campbell B; Churilov L; Yassi N; Yan B; Valente M; Sharobeam A; Balabanski A; Dos Santos A; Ng F; Langenberg F; Stephenson M; Smith K; Bernard S; Thijs V; Cloud G; Choi P; Ma H; Wijeratne T; Chen C; Olenko L; Davis SM; Donnan GA; Parsons M
BMJ Open; 2022 Apr; 12(4):e056573. PubMed ID: 35487712
[TBL] [Abstract][Full Text] [Related]
15. Non-immunogenic recombinant staphylokinase versus alteplase for patients with acute ischaemic stroke 4·5 h after symptom onset in Russia (FRIDA): a randomised, open label, multicentre, parallel-group, non-inferiority trial.
Gusev EI; Martynov MY; Nikonov AA; Shamalov NA; Semenov MP; Gerasimets EA; Yarovaya EB; Semenov AM; Archakov AI; Markin SS;
Lancet Neurol; 2021 Sep; 20(9):721-728. PubMed ID: 34418399
[TBL] [Abstract][Full Text] [Related]
16. Tenecteplase versus standard of care for minor ischaemic stroke with proven occlusion (TEMPO-2): a randomised, open label, phase 3 superiority trial.
Coutts SB; Ankolekar S; Appireddy R; Arenillas JF; Assis Z; Bailey P; Barber PA; Bazan R; Buck BH; Butcher KS; Camden MC; Campbell BCV; Casaubon LK; Catanese L; Chatterjee K; Choi PMC; Clarke B; Dowlatshahi D; Ferrari J; Field TS; Ganesh A; Ghia D; Goyal M; Greisenegger S; Halse O; Horn M; Hunter G; Imoukhuede O; Kelly PJ; Kennedy J; Kenney C; Kleinig TJ; Krishnan K; Lima F; Mandzia JL; Marko M; Martins SO; Medvedev G; Menon BK; Mishra SM; Molina C; Moussaddy A; Muir KW; Parsons MW; Penn AMW; Pille A; Pontes-Neto OM; Roffe C; Serena J; Simister R; Singh N; Spratt N; Strbian D; Tham CH; Wiggam MI; Williams DJ; Willmot MR; Wu T; Yu AYX; Zachariah G; Zafar A; Zerna C; Hill MD;
Lancet; 2024 Jun; 403(10444):2597-2605. PubMed ID: 38768626
[TBL] [Abstract][Full Text] [Related]
17. Association between brain imaging signs, early and late outcomes, and response to intravenous alteplase after acute ischaemic stroke in the third International Stroke Trial (IST-3): secondary analysis of a randomised controlled trial.
IST-3 collaborative group
Lancet Neurol; 2015 May; 14(5):485-96. PubMed ID: 25819484
[TBL] [Abstract][Full Text] [Related]
18. Safety and Efficacy of Tenecteplase Compared With Alteplase in Patients With Large Vessel Occlusion Stroke: A Prespecified Secondary Analysis of the ACT Randomized Clinical Trial.
Bala F; Singh N; Buck B; Ademola A; Coutts SB; Deschaintre Y; Khosravani H; Appireddy R; Moreau F; Phillips S; Gubitz G; Tkach A; Catanese L; Dowlatshahi D; Medvedev G; Mandzia J; Pikula A; Shankar JJ; Williams H; Field TS; Manosalva Alzate A; Siddiqui M; Zafar A; Imoukhoude O; Hunter G; Alhabli I; Benali F; Horn M; Hill MD; Shamy M; Sajobi TT; Swartz RH; Menon BK; Almekhlafi M
JAMA Neurol; 2023 Aug; 80(8):824-832. PubMed ID: 37428494
[TBL] [Abstract][Full Text] [Related]
19. Tenecteplase versus alteplase for thrombolysis in patients selected by use of perfusion imaging within 4·5 h of onset of ischaemic stroke (TASTE): a multicentre, randomised, controlled, phase 3 non-inferiority trial.
Parsons MW; Yogendrakumar V; Churilov L; Garcia-Esperon C; Campbell BCV; Russell ML; Sharma G; Chen C; Lin L; Chew BL; Ng FC; Deepak A; Choi PMC; Kleinig TJ; Cordato DJ; Wu TY; Fink JN; Ma H; Phan TG; Markus HS; Molina CA; Tsai CH; Lee JT; Jeng JS; Strbian D; Meretoja A; Arenillas JF; Buck BH; Devlin MJ; Brown H; Butcher KS; O'Brien B; Sabet A; Wijeratne T; Bivard A; Grimley RS; Agarwal S; Munshi SK; Donnan GA; Davis SM; Miteff F; Spratt NJ; Levi CR;
Lancet Neurol; 2024 Jun; ():. PubMed ID: 38880118
[TBL] [Abstract][Full Text] [Related]
20. Coagulation and Fibrinolytic Activity of Tenecteplase and Alteplase in Acute Ischemic Stroke.
Huang X; Moreton FC; Kalladka D; Cheripelli BK; MacIsaac R; Tait RC; Muir KW
Stroke; 2015 Dec; 46(12):3543-6. PubMed ID: 26514192
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
